Investor News

Acorda Therapeutics® Partners with Cardinal Health to Expand Sales Force for ZANAFLEX CAPSULES™


Hawthorne, NY November 10, 2005 – Acorda Therapeutics announced today that it has entered into an agreement with the Contract Sales and Services business of Cardinal Health (NYSE: CAH) Pharmaceutical Technologies and Services segment to expand the sales force for Acorda's Zanaflex Capsules™ (tizanidine hydrochloride) with approximately 160 contract sales representatives to address the primary care market.

The additional sales representatives will target approximately 4,000 primary care physicians. The primary care team will join Acorda's 14-person, in-house specialty sales force, which is focused on the neurology and physical medicine and rehabilitation markets. The combined sales and marketing infrastructure will be able to reach virtually all the potential high-volume prescribers of Zanaflex Capsules.

The two-year, performance-based agreement will provide Acorda with access to experienced sales professionals who will make dedicated physician visits on behalf of Zanaflex Capsules. Compensation is based on the achievement of performance objectives. Financial terms were not disclosed.

“We are delighted to have been selected by Acorda Therapeutics for this important initiative. The immediate addition of this sales force to promote Zanaflex Capsules will enable national coverage on an important segment of the market currently not covered by Acorda's sales force,” said Thomas Dimke, Senior Vice President and General Manager for Cardinal Health Contract Sales and Services.

Acorda acquired all US sales, marketing and distribution rights to Zanaflex Capsules and Zanaflex tablets from Elan Corporation, plc in July 2004. Zanaflex Capsules are a new, capsule formulation of tizanidine. Elan continues to manufacture Zanaflex Capsules for Acorda at its Athlone, Ireland facility. Zanaflex® is a registered trademark of Elan. Zanaflex Capsules™ is a trademark of Elan, for which registration is pending. Both trademarks are exclusively licensed to Acorda.

For full prescribing information, please go to

About Elan
Elan Corporation plc (NYSE: ELN) manufactures Zanaflex Capsules™ at its Elan Drug Technologies facility in Athlone, Ireland, using its proprietary SODAS® (Spheroid Oral Drug Absorption System) multiparticulate drug delivery technology. The Athlone campus, an FDA/European Medicines Agency-approved site, comprises of 421,000 square feet under roof, of which 138,000 square feet has dedicated, fully-equipped current good manufacturing practices ("cGMP") manufacturing capacity. Elan packages Zanaflex Capsules™ at its FDA approved manufacturing facility in Gainesville, Georgia.

About Acorda Therapeutics
Acorda Therapeutics, a privately-held biotechnology company, is developing therapies for multiple sclerosis, spinal cord injury and other disorders of the nervous system. Acorda's lead clinical-stage product is Fampridine-SR, which is in a Phase 3 clinical trial for MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord.

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At COMPANY NAME, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to COMPANY NAME to send you the requested Investor Email Alert updates.

* Required